An International Publications House

Albert Science International Organization

Connecting People With Pioneering Thought

Albert Science International Organization (ASIO) is international , peer-reviewed , open access , cum print version & online journals.
JOURNALS || ASIO Journal of Experimental Pharmacology & Clinical Research (ASIO-JEPCR) [ISSN: 2455-7080]

Author Names : Kanika Singhal
Page No. : 11-20  volume 3 issue 1
Article Overview


Cancer is often thought of as an untreatable, unbearably painful disease with no cure. However popular this view of cancer may be, it is exaggerated and over-generalized. Cancer is undoubtedly a serious and potentially life-threatening illness. However, it is a misconception to think that all forms of cancer are untreatable and deadly. The truth of the matter is that there are multiple types of cancer, many of which can today be effectively treated so as to eliminate, reduce or slow the impact of the disease on patients' lives. While a diagnosis of cancer may still leave patients feeling helpless and out of control, in many cases today there is cause for hope rather than hopelessness. cancer is a disease characterized by uncontrolled, uncoordinated and undesirable cell division. Unlike normal cells, cancer cells continue to grow and divide for their whole lives, replicating into more and more harmful cells. The abnormal growth and division observed in cancer cells is caused by damage in these cells' DNA (genetic material inside cells that determines cellular characteristics and functioning). There are a variety of ways that cellular DNA can become damaged and defective. Anti-Cancer drugs are medicines formulated to treat wide range of cancer. Cancer is the uncontrolled growth of cells that interfere with the growth of healthy cells. The usual treatments of Cancer are surgery, chemotherapy (treatment with anticancer drugs), radiation, or some combination of these methods. Anti-Cancer drugs are targeted to control and treat various Cancer like, Breast cancer, Cervical cancer, Small cell lung cancer, Head and Neck cancer, Ovarian cancer, Hodgkin’s and Non-Hodgkin’s lymphoma, Oesteo-sarcoma, Seminomas of testis, Myeloblastic leukemia, Lymphoblastic leukemia etc. The use and application of drugs synthesized or procured from natural or synthetic sources for cancer inhibition and cure is known as “chemotherapy” and the drugs are more commonly named as chemotherapeutic drugs. 

Keywords:  Normal cells, cancer cells, tumour, causes and treatment of cancer.                                         

  1. Ahles, T., Saykin, A., Furstenberg, C., & (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20(2), 485-493.

  2. American Cancer Society: Sexuality and cancer for the woman who has cancer and her partner. (2001) Publication #4657.

  3. American Cancer Society: Sexuality and cancer for the man who has cancer and his partner. (2001) Publication #4658.

  4. Schover, L. R. (1997). Sexuality and fertility after cancer. New York: John Wiley & Sons.

  5. Skeel, R. (Ed.). (1999). Handbook of cancer chemotherapy. Philadelphia: Lippincott, Williams & Wilkins.

  6. Pisarnthanarax, N., & Duvic M. (2002). Dermatologic complications of cancer chemotherapy. In JF Holland & E. Frei (Eds.), Cancer Medicine (pp. 2271-2278). Hamilton, Ontario: BC Decker Inc.

  7. Gacsedi, R. A. (2002). Massage therapy for patients with cancer. Clinical Journal of Oncology Nursing, 6(1), 52-54.

  8. Gordon, K. B., Tajuddin, A., & Guitart, J. (1995). Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer, 75(8), 2169-2173.

  9. Lynch, M. P. (2000). Depression in the cancer patient. Nurse Practioner SIG(Nov), 4-5.

  10. Mortimer J, & Anderson I. (1990). Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemotherapy and Pharmacology, 26, 449-452.

  11. Schwartz, S., & Plawecki, H. (2002). Consequences of chemotherapy on the sexuality of patients with lung cancer. Clinical Journal of Oncology Nursing, 6(4).

  12. Shelton, B. K., & Turnbough, L. (1996). Flu-like syndrome. In S. Groenwald (Ed.), Cancer Symptom Management (pp. 59-71). Boston, MA: Jones and Bartlett.

  13. Sherry VW. (2001). Taste alterations among patients with cancer. Clinical Journal of Oncology Nursing, 6(2), 73-77.

  14. Skeel, R. (Ed.). (1999). Handbook of cancer chemotherapy. Philadelphia: Lippincott, Williams & Wilkins.

  15. Weihofen, D., & Marino, C. (1998). The cancer survival cookbook. New York: John Wiley & Sons.

  16. Yarbro, C. H., Frogge, M. H., Goodman, M., & Groenwald, S. L. (Eds.). (1999). Cancer symptom management (5th ed.). Boston, MA: Jones and Barlett.

  17. Anticancer: A New Way of Life, David Servan Schreiber MD 2007.

  18. A Dietitian’s Cancer Story,Diana Dyer, MS RD. 6thEdition, 2002.

  19. Felici A.; J. Verweij; A. Sparreboom (2002). "Dosing strategies for anticancer drugs: 

    1. the good, the bad and body-surface area". Eur J Cancer 38 (13): 1677–84.

  20. Skeel RT (2003). Handbook of Cancer Chemotherapy (paperback) (6th ed.). Lippincott Williams & Wilkins.

  21. Chabner B, Longo DL (2005). Cancer Chemotherapy and Biotherapy: Principles and Practice (4th ed.). Philadelphia: Lippincott Willians & Wilkins.

  22. Madan V, Lear JT, Szeimies RM (Feb 2010). "Non-melanoma skin cancer". Lancet 375 (9715): 673–85.

  23. Donald Pinkel (August 1958). "The Use of Body Surface Area as a Criterion of Drug Dosage in Cancer Chemotherapy". Cancer Res 18 (7): 853–6.

  24. Kaldate RR; Haregewoin A; Grier CE; Hamilton SA; McLeod HL. "Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6". Oncologist 17 (3): 296–302.

  25. Siddik ZH (2005). Mechanisms of Action of Cancer Chemotherapeutic Agents: DNA-Interactive Alkylating Agents and Antitumour Platinum-Based Drugs. John Wiley & Sons, Ltd.

  26. Adjei AA (Jun 2004). "Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent". Clinical Cancer Research 10 (12 Pt 2): 4276s–4280s.

  27. Möller MG, Salwa S, Soden DM, O'Sullivan GC (Nov 2009). "Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma". Expert Review of Anticancer Therapy 9 (11): 1611–1630.

  28. DeVita VT, Chu E (Nov 2008). "A history of cancer chemotherapy". Cancer Research 68 (21): 8643–53.

  29. Fenn JE, Udelsman R (Mar 2011). "First use of intravenous chemotherapy cancer treatment: rectifying the record". Journal of the American College of Surgeons 212 (3): 413–417.

  30. Minchinton AI, Tannock IF (Aug 2006). "Drug penetration in solid tumours". Nature Reviews. Cancer 6 (8): 583–92.

  31. Deeken JF, Löscher W (Mar 2007). "The blood-brain barrier and cancer: transporters, treatment, and Trojan horses". Clinical Cancer Research 13 (6): 1663–74.